United Therapeutics Corporation v. Liquidia Technologies, Inc.

District Court, D. Delaware·Decided April 29, 2025·No. 1:23-cv-00975·Unknown

Opinion

INT HEU NITSETDA TDEISS TRCIOCUTR T FORT HED ISTRIOCFTD ELAWARE UNITETDH ERAPEUTICS ) CORPORATION, ) ) Plaintiff, CivAicltN ioo2.n3 -975-RGA-SRF ) ) V. ) ) LIQUITDEAC HNOLOIGNICE.S,, ) ) Defendant. ) MEMORANDOURMD ER AtW ilmitnhg2it9sotd nhao yAf p r2i0l2,t5 hc,eo uhratvc ionngs itdhpeearr teide s' letter osnup blmaiiUsnnstiTiithoffeen drs a peutic(s" PCloarpmioonrtttaiisotofft in'ro )in k'es portoitfoh rnees pe lxypr eerptoo Dfrr tN.si chHoilalanlDsd r S .t epOhgaenn (sDt2.a9Id5.,; D.2I9.7a )nd,de fenLdianqtu Tiedcihan oIlnoc(g."i'Deses fe,n mdoatntitsoo"t n)r p iokreto ifons three pelxypr eerpotoDf rr Rt.o nAa.lT dh is(tDe2.d9I,D6. .; 2I 9.8I )TI, SO RDERtEhDta hte pendmiontgaiD to. n2l 7.i6 as d draefossl sleodw s: 1.Plainmtoitfitroossn t rpiokret oifto hnrese pelxyp reerptoo fDr rtN. i cholas HiilDslE NIwEiDt hporuetj uPdliacimen.ot vtiesoffst rpiakrea g1r6ta 1op7 7h,7ts 8o 1 9,4 t9o6 1,0 6,t 1o11 1a20n,1 d 4 t81o 7 o9Df r . Hielxlp'rese rpatron ertdppot lr ye cDlrHu.id lel frotme staittfyr irineaggl a trhdoeip nigni ithnoo nspsea ragorfta hrpeeh psPo lrati.hn aatsli sffo filaem do ttieoox nc lDurHd.ie lo lp'isnp iuornst uDoana tu bveM.re tr rDeolPwlh arImn.c,. , 50U9. 5S7.(9 1 99(3D)2..81D 4..; 2I 9.a5 1t nF.o1pr)u rpoofts hedisis s cdoivseptruhyte e , couforctu osneolsny w hetthhieedr e nptairfiaegdirD nar Hp.ih lsrl e'prsle ypu onrttio mffeelry neowp inoinio nnvsa alniiddn ietqyuc iotnadwbuilcthetor ,ue ta cthhien gs umbesrtoiaftn st ive Dr. Hill’s reply report and any issues that are briefed and pending decision before the District Judge. 2. Plaintiff first contends that Dr. Hill’s opening expert report on inequitable conduct failed to address the cumulativeness of the allegedly withheld references over information the patent examiner already possessed. (D.I. 295 at 2) Plaintiff also raises this argument in its Daubert motion to exclude Dr. Hill’s opinions. (D.I. 285 at 2, 13-14) (“[T]he relevant caselaw provides that the withheld references must be non-cumulative to the material already before the Examiner, but Dr. Hill’s Opening Report contains no analysis of cumulativeness.”). It is wasteful of judicial resources to seek relief from two judicial officers on the same issue. The court declines to consider Dr. Hill’s alleged failure to address the cumulativeness of the withheld references for purposes of inequitable conduct because this issue is currently pending before the District Judge. 3. Next, Plaintiff contends that Dr. Hill’s opening expert report on prior sale and public use fails to describe whether the claimed invention worked for its intended purpose or whether it was put in the possession of the public by disclosure in enabling documents or drawings. (D.I. 295 at 2) But a review of Dr. Hill’s opening expert report confirms that he opined on enabling documents and drawings, including Agarwal 2015, Faria-Urbina 2018, and Parikh 2016, and he described the prior use of Tyvaso® to treat pulmonary hypertension and interstitial lung disease (“PH-ILD”). (D.I. 297, Ex. E at J 131-93) Because Dr. Hill’s opinions on prior sale and public use were timely disclosed in his opening expert report, the court need not engage in a Pennypack analysis. See ARM Ltd. v. Qualcomm Inc., C.A. No. 22-1146-MN, 2024 WL 5504800, at *2 (D. Del. Dec. 10, 2024) (declining to evaluate the Pennypack factors where reply expert opinions were directly responsive to rebuttal report and were therefore timely).

4. Plaintiff's conditional motion to strike portions of the reply expert report of Stephan Ogenstad, Ph.D., is DENIED without prejudice. Plaintiff conditionally moves to strike paragraphs 47 to 54 and 95 to 289 of Dr. Ogenstad’s reply expert report and to preclude Dr. Ogenstad from testifying at trial regarding the opinions in those paragraphs. Plaintiffs motion to strike Dr. Ognstad’s reply report is conditioned on whether the court grants Defendant’s motion to strike portions of Dr. Thisted’s reply report. (D.I. 295 at 4) Plaintiff admits its argument on this issue is a fallback position reflexive to Defendant’s motion to strike Dr. Thisted’s reply opinions. (/d.) Plaintiff further admits the issue of whether both sides’ biostatistician experts should be stricken is the subject of parallel Daubert motions. (/d.; D.I. 278; 286) The court will not address this motion to strike due to the parallel Daubert motions pending before the District Judge, and the outcome of this issue is subject to the District Judge’s ruling on the Daubert motions. 5. Defendant’s motion to strike portions of the reply expert report of Dr. Ronald A. Thisted is DENIED without prejudice. Defendant moves to strike as untimely paragraphs 17, 88, 106, 109, 138, 139, 141, 227, 228, 229, 235, 237, 250, 251, 252, 257, 264, 268, 273, 279, 280, 284, 285, 289, 293, 307, 308, 314 and 320 of Dr. Thisted’s reply expert report. According to Defendant, these paragraphs disclose affirmative opinions regarding infringement that exceed the scope of permissible reply expert testimony. (D.I. 296 at 1) Plaintiff argues in opposition that Dr. Thisted’s reply opinions are proper because they respond to issues raised for the first time by Defendant’s expert, Dr. Channick, in rebuttal. (D.I. 298 at 1) However, Plaintiff's responsive submission fails to draw a connection for the court between the specific portions of Dr. Channick’s allegedly new opinions and the paragraphs of Dr. Thisted’s report which are the subject of the pending motion to strike. (/d. at 2-3)

6. In its moving submission, Defendant does not confront the issue of whether Dr. Channick’s rebuttal report injected new issues in the case that would arguably open the door for Dr. Thisted’s reply in opposition. In its responsive letter brief, Plaintiff summarizes the opinions raised in Dr. Channick’s rebuttal report without meaningfully addressing the timeliness of that disclosure or giving the court a baseline reference for determining whether such opinions are actually new. (D.I. 298) Moreover, Plaintiff does not cross-reference the specific paragraphs in Dr. Channick’s report that allegedly correspond to the challenged paragraphs in Dr. Thisted’s reply report. Thus, the court is left to compare on its own which of Dr. Thisted’s opinions Plaintiff contends respond to the “new” opinions expressed in Dr. Channick’s rebuttal report. (D.I. 298, Exs. 2,6) The court expects that, had the parties meaningfully met and conferred, Defendant’s moving submission would have anticipated and addressed Plaintiffs position that Dr. Thisted’s reply report responds to allegedly “new” opinions in Dr. Channick’s rebuttal report. 7. The briefing on this motion to strike suggests a breakdown in the meet and confer process. The joint motion for a discovery dispute teleconference represents that the parties met and conferred on March 6, 2025, and they have had ample time since that filing to engage in further meet and confer efforts. (D.I. 276) The court’s ability to resolve the dispute is hampered where, as here, the parties talk past each other in their letter briefs. On this incomplete record, Defendant has not shown that the extreme sanction of excluding certain of Dr. Thisted’s opinions is justified. Konstantopoulos v. Westvaco Corp., 112 F.3d 710, 719 (3d Cir. 1997) (citing Meyers v. Pennypack Woods Home Ownership Ass'n, 559 F.2d 894, 904-05 (3d Cir. 1977)). Consequently, Defendant’s motion to strike Dr. Thisted’s allegedly untimely opinions in his reply expert report is DENJED.

8. Defendant also moves to strike the following paragraphs of Dr. Thisted’s reply report as duplicative of opinions raised in Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

United Therapeutics Corporation v. Liquidia Technologies, Inc., (D. Del. 2025).

United Therapeutics Corporation v. Liquidia Technologies, Inc. (United Therapeutics Corporation v. Liquidia Technologies, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related